SAN DIEGO, Dec. 14, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, engaged in the development of targeted cancer therapies, today announced the filing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback